Teva Pharmaceutical Industries Limited Stock Prediction and Forecast [TEVA]

AI-generated source summary

The analysis discusses Teva Pharmaceutical Industries, noting several negative signals but upgrading the analysis conclusion from a sell to a hold candidate. It identifies resistance at $19.68 and support at $16.83. The stock exhibits medium daily movements, indicating medium risk. A sell signal from a pivot top was found 12 days prior. Analyst ratings indicate a sell. The P/E ratio is -138.64. A suggested stop-loss is set at $17.91. Recent insider trading shows more sales than buys. Upward corrections may face resistance at $19.18 and $19.41. A breakout above these levels may issue buy signals, while a sell signal occurred from a pivot top on October 8, 2025. The trend suggests a potential change of 22.99% over the next 3 months with a possible return ranging from 22.99% to 35.93%. A 12-month analysis projects a change of -0.0951%, with performance fluctuating between -32.47% and 19.95%.

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   25 Oct 2025, 03:48 UTC

   The analyst published the original source item.

2. First prediction resolved

   27 Oct 2025, 13:30 UTC

   The first evaluable outcome in this case reached a terminal result.

3. Case evaluation completed

   27 Oct 2025, 13:30 UTC

   All evaluable predictions in this case reached terminal outcomes.

4. Source recorded by Tahlil Plus

   18 May 2026, 20:23 UTC

   The public source was preserved as the evidence record for this case.

5. Market predictions extracted

   18 May 2026, 20:47 UTC

   1 eligible signal linked to this case.

6. Outcome tracking started

   02 Jul 2026, 02:14 UTC

   Tahlil Plus began monitoring the extracted predictions.